Treatment of neurological pathology and inflammation in Machado–Joseph disease through in vivo self-assembled siRNA
Brain · 2025
DOI: 10.1093/brain/awae304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Zhizong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Res…. Hauptthemen laut MEDLINE: Machado-Joseph Disease, Ataxin-3, RNA, Small Interfering. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Training Program of the Major Research Plan of the National Natural Science Foundation of China, Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study.
Abstract (Originalsprache)
Machado–Joseph disease, also known as spinocerebellar ataxia type 3 (MJD/SCA3), is a fatal autosomal dominant hereditary ataxia characterized by cerebellar ataxia resulting from the abnormal expansion of CAG repeats in exon 10 of the ATXN3 gene. At present, there is no effective treatment for SCA3. Small interfering RNAs (siRNAs) are emerging as potential therapeutic strategies to target the disease-causing mutant ATXN3 (mATXN3) protein specifically. However, the efficiency of delivery of siRNAs remains a major obstacle for clinical application, particularly in brain disorders. The aim of this study was to develop a synthetic biology strategy to reprogram the host liver as a tissue chassis to induce and deliver in vivo self-assembled siRNAs to target the ATXN3 gene. A synthetic construct directed by a cytomegalovirus promoter was designed to encode a neuron-targeting rabies virus glycoprotein tag and mATXN3-siRNA. After intravenous injection, the synthetic construct was taken up by mouse livers, which were then reprogrammed to enable the self-assembly, production and secretion of small extracellular vesicles encapsulating mATXN3-siRNA. The small extracellular vesicle-encapsulated mATXN3-siRNA was transported through the endogenous circulating system of small extracellular vesicles, crossing the blood–brain barrier and reaching the cerebellar cortex and spinal cerebellar tract, where they silenced the ATXN3 gene. Treatment with the synthetic construct for 8 or 12 weeks led to significant improvements in motor balance ability and reduction of cerebellar atrophy in YACMJD84.2 transgenic mice. The number of Purkinje cells in the cerebellar cortex was significantly increased, and the loss of myelin basic protein was reduced. Moreover, the quantity of neurotoxic nuclear inclusion bodies and the expression of glial fibrillary acidic protein, which promotes neuroinflammation in activated astrocytes, were decreased significantly. The synthetic construct facilitated the generation and delivery of in vivo self-assembled siRNA to the cerebellar cortex and spinal cerebellar tract, thereby inhibiting the expression of mATXN3 protein. This treatment successfully addressed motor impairments, alleviated neuropathological phenotypes and mitigated neuroinflammation in YACMJD84.2 transgenic mice. Our strategy effectively overcomes the primary challenges associated with siRNA therapy for cerebellar ataxia, offering a promising avenue for future clinical treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Inst…
- Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, The First Affiliated Hospital, Su…
- Department of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
- Research Unit of Extracellular RNA, Chinese Academy of Medical Sciences, Nanjing, Jiangsu 210023, China.
- Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, Jiangsu 210023, China.
Förderung
- National Natural Science Foundation of China
- Training Program of the Major Research Plan of the National Natural Science Foundation of China
- Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study
- Provincial Natural Science Foundation of Jiangsu
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Li, Z., Du, X., Yang, Y., Zhang, L., Chen, P., Kan, Y., Pan, J., Lin, L., Liu, D., Jiang, X., Zhang, C. Y., Pei, Z., & Chen, X. (2025). Treatment of neurological pathology and inflammation in Machado–Joseph disease through in vivo self-assembled siRNA. Brain. https://doi.org/10.1093/brain/awae304
Vancouver
Li Z, Du X, Yang Y, Zhang L, Chen P, Kan Y, et al. Treatment of neurological pathology and inflammation in Machado–Joseph disease through in vivo self-assembled siRNA. Brain. 2025. doi:10.1093/brain/awae304
BibTeX
@article{Li2025,
author = {Li, Zhizong and Du, Xinghu and Yang, Yixuan and Zhang, Li and Chen, Penglu and Kan, Yansheng and Pan, Jinmeng and Lin, Lishan and Liu, Ding and Jiang, Xiaohong and Zhang, Chen-Yu and Pei, Zhong and Chen, Xi},
title = {Treatment of neurological pathology and inflammation in Machado–Joseph disease through in vivo self-assembled siRNA},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awae304}
}
EUVIMED